Europe needs to collect more plasma – Improving patient access to plasma-derived medicines

In the coming decade, it is expected that more European patients will need access to plasma-derived medicines.

Every year, more patients across the EU are diagnosed with life-threatening plasma protein-related disorders, such as immune deficiencies, immune-mediated peripheral neuropathies, hereditary angioedema, alpha-1 antitrypsin deficiencies, haemophilia, and other bleeding disorders. In many cases, plasma-derived medicines are the only option to treat these rare diseases.